Concetta Valentina Tropeano
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Concetta Valentina Tropeano has a total of 23 co-authors. Here are the top co-authors by number of shared publications:
- Aldo Roda
Department of Chemistry “G. Ciamician”, University of Bologna, 40126 Bologna, Italy
1 shared publication - Alessandra Maresca
IRCCS Istituto delle Scienze Neurologiche di Bologna, Programma di Neurogenetica, Bologna, Italy
1 shared publication Alessandro Rapone
Department of Biomedical and Neuromotor Sciences, University of Bologna , Bologna 40126
1 shared publication- Anna Ghelli
Programma di Neurogenetica, IRCCS Istituto delle Scienze Neurologiche di Bologna , Bologna 40139
1 shared publication - Claudia Zanna
Department of Pharmacy and Biotechnology (FaBiT), University of Bologna, Bologna, Italy
1 shared publication - Emanuele Porru
Occupational Medicine Unit, Department of Medical and Surgical Science, Alma Mater Studiorum, University of Bologna, 40138 Bologna, Italy
1 shared publication
Latest Publications
- Open Access
- 4 March 2025
- Published by Oxford University Press (OUP) in Brain Communications
- Vol. 7 (2) , fcaf125
Elevated circulating cell-free mitochondrial DNA level in cerebrospinal fluid of narcolepsy type 1
Narcolepsy type 1 (NT1) is a rare neurological disorder characterized by excessive daytime sleepiness and cataplexy, thought to result from an autoimmune process targeting the hypothalamic hypocretin-producing neurons. Aiming to add clues to the latter hypothesis, we investigated circulating cell-free mitochondrial DNA (ccf-mtDNA) levels in cerebrospinal fluid (CSF), a possible biomarker for neurodegeneration, neuroinflammation or immune activation, from 46 NT1 patients with low CSF hypocretin-1, compared with 32 controls. We found significantly increased ccf-mtDNA levels in NT1 patients compared with controls, which negatively correlated with CSF hypocretin-1 concentrations. Additionally, higher ccf-mtDNA levels were observed in patients with elevated number of sleep onset rapid eye movement periods. These observations imply that increased levels of ccf-mtDNA associate with reduced CSF hypocretin-1 concentrations leading to greater alteration in sleep architecture. Furthermore, cytokine profiling in CSF revealed significant changes in interleukins 6 and 18 in NT1 patients, suggesting an active neuroinflammatory process possibly linked to ccf-mtDNA release, thus pointing to a specific inflammatory signature in NT1. These findings hint a potential mitochondrial dysfunction and neuroinflammation in NT1. Further studies are needed to elucidate the underlying mechanisms and how this may reflect on therapy.
- 4 March 2025
- Published by Oxford University Press (OUP) in Brain Communications
- Vol. 7 (2) , fcaf125
Open AccessElevated circulating cell-free mitochondrial DNA level in cerebrospinal fluid of narcolepsy type 1
Narcolepsy type 1 (NT1) is a rare neurological disorder characterized by excessive daytime sleepiness and cataplexy, thought to result from an autoimmune process targeting the hypothalamic hypocretin-producing neurons. Aiming to add clues to the latter hypothesis, we investigated circulating cell-free mitochondrial DNA (ccf-mtDNA) levels in cerebrospinal fluid (CSF), a possible biomarker for neurodegeneration, neuroinflammation or immune activation, from 46 NT1 patients with low CSF hypocretin-1, compared with 32 controls. We found significantly increased ccf-mtDNA levels in NT1 patients compared with controls, which negatively correlated with CSF hypocretin-1 concentrations. Additionally, higher ccf-mtDNA levels were observed in patients with elevated number of sleep onset rapid eye movement periods. These observations imply that increased levels of ccf-mtDNA associate with reduced CSF hypocretin-1 concentrations leading to greater alteration in sleep architecture. Furthermore, cytokine profiling in CSF revealed significant changes in interleukins 6 and 18 in NT1 patients, suggesting an active neuroinflammatory process possibly linked to ccf-mtDNA release, thus pointing to a specific inflammatory signature in NT1. These findings hint a potential mitochondrial dysfunction and neuroinflammation in NT1. Further studies are needed to elucidate the underlying mechanisms and how this may reflect on therapy.
- 9 December 2019
- Published by Elsevier in Biochimica et Biophysica Acta (BBA) - Bioenergetics
- Vol. 1861 (2) , 148133
Fine-tuning of the respiratory complexes stability and supercomplexes assembly in cells defective of complex III
- 9 December 2019
- Published by Elsevier in Biochimica et Biophysica Acta (BBA) - Bioenergetics
- Vol. 1861 (2) , 148133
Fine-tuning of the respiratory complexes stability and supercomplexes assembly in cells defective of complex III